Sana (SANA) CEO Steve Harr vests RSUs and uses 24,345 shares for tax
Rhea-AI Filing Summary
Sana Biotechnology President & CEO Steve Harr reported routine equity compensation activity. On March 6 and 7, 2026, he exercised restricted stock units to acquire a total of 91,666 shares of common stock at $0.00 per share. Related to these vestings, on March 9, 2026, 11,526 shares and 12,819 shares of common stock were disposed of at approximately $3.13 and $3.10 per share, respectively, to satisfy tax liabilities. Following these transactions, Harr directly holds 7,944,251 shares of Sana common stock, with additional indirect holdings reported through family trusts. Footnotes explain that the RSU awards vest over several years, contingent on Harr’s continued service with Sana.
Positive
- None.
Negative
- None.
Insights
CEO exercised RSUs and covered taxes with share withholding, a routine compensation event.
The filing shows Steve Harr converting restricted stock units into 91,666 common shares at $0.00 per share. This is standard RSU vesting, not an open-market purchase, and reflects equity compensation becoming actual stock.
To handle tax obligations from these vestings, Harr delivered a total of 24,345 shares at prices near $3.10 per share. These F-code transactions are tax-withholding dispositions, not discretionary sales. He still directly holds 7,944,251 shares, indicating a large remaining equity position.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 11,526 | $3.13 | $36K |
| Tax Withholding | Common Stock | 12,819 | $3.10 | $40K |
| Exercise | Restricted Stock Units | 50,000 | $0.00 | -- |
| Exercise | Common Stock | 50,000 | $0.00 | -- |
| Exercise | Restricted Stock Units | 41,666 | $0.00 | -- |
| Exercise | Common Stock | 41,666 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Brian L. Harr is the trustee of these trusts, whose sole beneficiaries are members of the reporting person's immediate family. Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. The award vested as to 25% of the restricted stock units on March 6, 2026, and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. The award vested as to 25% of the restricted stock units on each of March 7, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of March 7, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
